Holen Sie sich die Stockscreener-App
57.08
0.21%
-0.32
Handel nachbörslich:
57.08
Schlusskurs vom Vortag:
$57.40
Offen:
$56.21
24-Stunden-Volumen:
648.92K
Relative Volume:
0.70
Marktkapitalisierung:
$1.09B
Einnahmen:
$90.12M
Nettoeinkommen (Verlust:
$-276.06M
KGV:
-39.10
EPS:
-1.46
Netto-Cashflow:
$-193.47M
1W Leistung:
-1.24%
1M Leistung:
+17.67%
6M Leistung:
+9,385%
1J Leistung:
+4,239%
1-Tages-Spanne:
$55.50
$58.29
1-Wochen-Bereich:
$52.91
$59.64
52-Wochen-Spanne:
$0.432
$62.95
Nektar Therapeutics Stock (NKTR) Company Profile
Firmenname
Nektar Therapeutics
Sektor
Branche
Telefon
(415) 482-5300
Adresse
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Vergleichen Sie NKTR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
57.08 | 1.09B | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-24 | Bestätigt | BTIG Research | Buy |
| 2025-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2025-04-11 | Hochstufung | Jefferies | Hold → Buy |
| 2025-03-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-01-08 | Eingeleitet | B. Riley Securities | Buy |
| 2024-12-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-09-30 | Fortgesetzt | BTIG Research | Buy |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-11-09 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-05-10 | Hochstufung | Jefferies | Underperform → Hold |
| 2023-02-24 | Herabstufung | Jefferies | Hold → Underperform |
| 2022-08-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-31 | Fortgesetzt | Jefferies | Hold |
| 2022-04-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-15 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-14 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-03-14 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-14 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2022-03-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-11-08 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-09-10 | Eingeleitet | BofA Securities | Neutral |
| 2021-06-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-02-22 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-01-06 | Eingeleitet | Stifel | Hold |
| 2020-09-14 | Eingeleitet | JP Morgan | Neutral |
| 2020-06-10 | Herabstufung | CFRA | Hold → Sell |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-04-22 | Eingeleitet | The Benchmark Company | Buy |
| 2020-03-30 | Hochstufung | Goldman | Sell → Neutral |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-08 | Herabstufung | Goldman | Buy → Sell |
| 2019-08-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-08-09 | Herabstufung | Jefferies | Buy → Hold |
| 2019-08-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-03-15 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-06-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2018-06-04 | Bestätigt | H.C. Wainwright | Buy |
| 2018-04-20 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-04-13 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-04-06 | Bestätigt | Mizuho | Buy |
| 2018-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
Alle ansehen
Nektar Therapeutics Aktie (NKTR) Neueste Nachrichten
Will Nektar Therapeutics stock benefit from AI adoptionJuly 2025 Closing Moves & Stepwise Entry/Exit Trade Alerts - newser.com
Is Nektar Therapeutics stock a good choice for value investorsShort Setup & Weekly Chart Analysis and Guides - newser.com
Using economic indicators to assess Nektar Therapeutics potentialEarnings Risk Summary & Real-Time Chart Breakout Alerts - newser.com
Evaluating Nektar Therapeutics with trendline analysis2025 Top Gainers & Reliable Price Breakout Signals - newser.com
How Investors Are Reacting To Nektar Therapeutics (NKTR) Securing FDA Fast Track For Eczema Drug Candidate - simplywall.st
FDA Fast Track for Eczema Therapy Could Be a Game Changer for Nektar Therapeutics (NKTR) - Yahoo Finance
Nektar Therapeutics (NKTR): Assessing Valuation After a Strong Multi-Month Share Price Rally - Yahoo Finance
Why retail investors pile into Nektar Therapeutics stockWeekly Investment Report & Verified Stock Trade Ideas - newser.com
Best data tools to analyze Nektar Therapeutics stockJuly 2025 Breakouts & Precise Trade Entry Recommendations - newser.com
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street - MSN
Custom strategy builders for tracking Nektar TherapeuticsVolume Spike & Expert Curated Trade Setups - newser.com
Quantitative breakdown of Nektar Therapeutics recent moveQuarterly Portfolio Report & High Accuracy Trade Signal Alerts - newser.com
Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September - MSN
Wealth Enhancement Advisory Services LLC Reduces Stake in Nektar Therapeutics $NKTR - MarketBeat
Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today - MSN
Nektar Therapeutics' (NKTR) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
What MACD and RSI say about Nektar TherapeuticsJuly 2025 Fed Impact & Smart Money Movement Tracker - newser.com
Moderate to Severe Atopic Dermatitis Pipeline Drugs Insights Report 2025: Emerging Therapies, Clinical Developments, and Drug Insights by DelveInsight - The Globe and Mail
How Nektar Therapeutics (ITH0) stock responds to job market shiftsNew Guidance & Reliable Price Breakout Alerts - newser.com
Sector ETF performance correlation with Nektar Therapeutics2025 Technical Patterns & AI Driven Price Predictions - newser.com
Gainplan LLC Buys New Shares in Nektar Therapeutics $NKTR - MarketBeat
Public Employees Retirement System of Ohio Sells 121,001 Shares of Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NKTR): Examining Valuation After Breakthrough Eczema Drug Trial Results Spark Investor Interest - Sahm
How Nektar Therapeutics (ITH0) stock reacts to weak economyDividend Hike & Real-Time Stock Movement Alerts - newser.com
What analysts say about Nektar Therapeutics stockSwing Trading Watchlist & Build Wealth With Expert Timing Advice - earlytimes.in
Real time social sentiment graph for Nektar TherapeuticsTrade Entry Report & Fast Exit and Entry Strategy Plans - newser.com
Is a relief rally coming for Nektar Therapeutics holdersTrade Entry Summary & Advanced Swing Trade Entry Plans - newser.com
How analysts rate Nektar Therapeutics stock today2025 Support & Resistance & Long-Term Safe Return Strategies - newser.com
Why Nektar Therapeutics (NKTR) Is Up 8.8% After Positive Phase 2b Rezpegaldesleukin Data at EADV - simplywall.st
Nektar Therapeutics (NASDAQ:NKTR) Reaches New 52-Week HighTime to Buy? - MarketBeat
Nektar Therapeutics stock hits 52-week high at 61.24 USD By Investing.com - Investing.com South Africa
Nektar Therapeutics stock hits 52-week high at 61.24 USD - Investing.com
The biotech scorecard for the fourth quarter: 36 stock-moving events to watch - statnews.com
Finanzdaten der Nektar Therapeutics-Aktie (NKTR)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):